Skip to main content
Top
Published in: Drugs & Aging 1/2001

01-01-2001 | Therapy in Practice

Management of Type 2 Diabetes Mellitus in the Elderly

Special Considerations

Author: Dr Julio Rosenstock

Published in: Drugs & Aging | Issue 1/2001

Login to get access

Abstract

The principles of managing type 2 diabetes mellitus in the elderly are no different from those in younger patients, but the priorities and therapeutic strategies need to be cautiously individualised. The objectives of treatment are to improve glycaemic control in a stepwise approach that involves nonpharmacological methods including diet and exercise, and pharmacological therapy including mixtures of oral antihyperglycaemic agents alone or in combination with insulin. Although the goals of treatment may be the same for elderly and younger patients, certain aspects of type 2 diabetes in the elderly require special consideration. Treatment decisions are influenced by age and life expectancy, comorbid conditions and severity of the vascular complications. Adherence to dietary therapy, physical activity, and medication regimens may be compromised by comorbid conditions and psychosocial limitations. Drug-induced hypoglycaemia has been the main consideration and the most serious potential complication.
In addition, the long term macrovascular and microvascular complications of type 2 diabetes are a source of significant morbidity and mortality. Indeed, vascular and neuropathic complications are already present at the time of diagnosis in a significant number of patients, and the impact of improved diabetes control depends on the age and life expectancy of the patient. Age-related changes in pharmacokinetics and the potential for adverse effects and drug interactions should also be considered when choosing appropriate pharmacological therapy.
In general, a conservative and stepwise approach to the treatment of the elderly patient with type 2 diabetes is suggested; treatment may be initiated with monotherapy, followed by early intervention with a combination of oral agents including a sulphonylurea as a foundation insulin secretagogue in addition to a supplemental insulin sensitiser. Insulin therapy is eventually required if significant hyperglycaemia [glycosylated haemoglobin (HbA1c) >8%] persists despite oral combination therapy. Combination therapy with evening insulin and a long-acting sulphonylurea such as glimepiride is an effective strategy to improve hyperglycaemia in the elderly patient with type 2 diabetes in whom polypharmacy with oral agents is unsuccessful. In addition, such a regimen is simple to follow for the patient who may not be able to adhere to a more complicated insulin regimen. Hyperglycaemia in the elderly can be managed well with practical intervention and a straightforward treatment plan to enhance compliance. Optimal glycaemic control should be possible for every patient if treatment is individualised; however, strict glycaemic control may not be achievable in all patients or even desirable in many elderly patients.
Literature
1.
go back to reference Lipson LG. Diabetes in the elderly: diagnosis, pathogenesis, and therapy. Am J Med 1986; 80 Suppl. 5A: 10–21PubMedCrossRef Lipson LG. Diabetes in the elderly: diagnosis, pathogenesis, and therapy. Am J Med 1986; 80 Suppl. 5A: 10–21PubMedCrossRef
2.
go back to reference Gossain VV, Carella MJ, Rovner DR. Management of diabetes in the elderly: a clinical perspective. J Assoc Acad Minority Phys 1994; 5: 22–31 Gossain VV, Carella MJ, Rovner DR. Management of diabetes in the elderly: a clinical perspective. J Assoc Acad Minority Phys 1994; 5: 22–31
3.
go back to reference Singh I, Marshall Jr MC. Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am 1995; 24: 255–72PubMed Singh I, Marshall Jr MC. Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am 1995; 24: 255–72PubMed
4.
go back to reference Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third national health and nutrition examination survey, 1988–1994. Diabetes Care 1998; 21: 518–24PubMedCrossRef Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third national health and nutrition examination survey, 1988–1994. Diabetes Care 1998; 21: 518–24PubMedCrossRef
6.
go back to reference American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998; 21: 296–309CrossRef American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998; 21: 296–309CrossRef
7.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRef
8.
go back to reference UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13CrossRef UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13CrossRef
9.
go back to reference van Boven AJ, Brugemann J, de Graeff PA, et al. The 4S study: implications for prescribing. Drugs 1996; 51: 507–14PubMedCrossRef van Boven AJ, Brugemann J, de Graeff PA, et al. The 4S study: implications for prescribing. Drugs 1996; 51: 507–14PubMedCrossRef
10.
go back to reference Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9
11.
go back to reference Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129: 681–9PubMed Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129: 681–9PubMed
12.
go back to reference Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57CrossRef Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57CrossRef
13.
go back to reference Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 16: 333: 1301–7CrossRef Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 16: 333: 1301–7CrossRef
14.
go back to reference Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 22: 253–9 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 22: 253–9
15.
go back to reference Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–73PubMedCrossRef Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–73PubMedCrossRef
16.
go back to reference Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynbamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8: 461–6PubMedCrossRef Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynbamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8: 461–6PubMedCrossRef
17.
go back to reference Tuck ML. Obesity. In: Swales JD, editor. Textbook of hypertension. Cambridge (MA): Blackwell Scientific Publications, 1994: 572–92 Tuck ML. Obesity. In: Swales JD, editor. Textbook of hypertension. Cambridge (MA): Blackwell Scientific Publications, 1994: 572–92
18.
go back to reference American Diabetes Association. Position Statement. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1997; 20Suppl. 1: S5–S13 American Diabetes Association. Position Statement. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1997; 20Suppl. 1: S5–S13
19.
go back to reference American Diabetes Association. Position Statement. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1997; 20Suppl. 1: S14–7 American Diabetes Association. Position Statement. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1997; 20Suppl. 1: S14–7
20.
go back to reference Lebovitz HE. Oral antidiabetic agents: the emergence of ∝-glucosidase inhibitors. Drugs 1992; 44Suppl. 3: 21–8PubMedCrossRef Lebovitz HE. Oral antidiabetic agents: the emergence of ∝-glucosidase inhibitors. Drugs 1992; 44Suppl. 3: 21–8PubMedCrossRef
21.
go back to reference Groop LC, DeFronzo RA. Sulfonylureas. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book, 1998: 96–101 Groop LC, DeFronzo RA. Sulfonylureas. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book, 1998: 96–101
22.
go back to reference Ilarde A, Tuck M. Treatment of non-insulin-dependent diabetes mellitus and its complications: a state of the artreview. Drugs Aging 1994; 4: 470–91PubMedCrossRef Ilarde A, Tuck M. Treatment of non-insulin-dependent diabetes mellitus and its complications: a state of the artreview. Drugs Aging 1994; 4: 470–91PubMedCrossRef
23.
go back to reference Skyler JS. Insulin therapy in type 2 diabetes mellitus. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book, 1998: 108–16 Skyler JS. Insulin therapy in type 2 diabetes mellitus. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book, 1998: 108–16
24.
go back to reference Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681–6PubMedCrossRef Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681–6PubMedCrossRef
25.
go back to reference UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87–92CrossRef UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87–92CrossRef
26.
go back to reference Rosskamp R, Wernicke-Panten K, Draeger E. Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 1996; 31 Suppl. S33–42PubMedCrossRef Rosskamp R, Wernicke-Panten K, Draeger E. Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 1996; 31 Suppl. S33–42PubMedCrossRef
27.
go back to reference Goldberg RB, Holvey SM, Schneider J. The Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996; 19: 849–56PubMedCrossRef Goldberg RB, Holvey SM, Schneider J. The Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996; 19: 849–56PubMedCrossRef
28.
go back to reference Rosenstock J, Samols E, Muchmore DB, et al, Glimepiride Study Group. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996; 19: 1194–9PubMedCrossRef Rosenstock J, Samols E, Muchmore DB, et al, Glimepiride Study Group. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996; 19: 1194–9PubMedCrossRef
29.
go back to reference Dills DG, Schneider J, Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996; 28: 426–9PubMedCrossRef Dills DG, Schneider J, Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996; 28: 426–9PubMedCrossRef
30.
go back to reference Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycemia in type 2 diabetic patients treated with glimepiride versus glibenclamide [abstract 157]. Diabetologia 2000; 43Suppl. 1: A40 Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycemia in type 2 diabetic patients treated with glimepiride versus glibenclamide [abstract 157]. Diabetologia 2000; 43Suppl. 1: A40
31.
go back to reference Langtry HD, Balfour JA. Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs 1998; 55: 563–84PubMedCrossRef Langtry HD, Balfour JA. Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs 1998; 55: 563–84PubMedCrossRef
32.
go back to reference Consoli A. Metformin. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book, 1998: 102–5 Consoli A. Metformin. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book, 1998: 102–5
33.
go back to reference DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541–9PubMedCrossRef DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541–9PubMedCrossRef
34.
go back to reference Johnson M, Krosnick A, Carson P, et al. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther 1998; 20: 691–8PubMedCrossRef Johnson M, Krosnick A, Carson P, et al. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther 1998; 20: 691–8PubMedCrossRef
35.
36.
go back to reference Rosenstock J. Pioglitazone reduces insulin resistance and improves beta-cell function in type 2 diabetes patients on longterm sulfonylurea therapy [abstract 1752]. 82nd Annual Meeting of the Endocrine Society. Program and Abstracts; 2000: Jun 21–4; Toronto (ON) Rosenstock J. Pioglitazone reduces insulin resistance and improves beta-cell function in type 2 diabetes patients on longterm sulfonylurea therapy [abstract 1752]. 82nd Annual Meeting of the Endocrine Society. Program and Abstracts; 2000: Jun 21–4; Toronto (ON)
37.
go back to reference Schneider R, Egan J, Houser V. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes [abstract]. Diabetes 1999; 42Suppl. 1: A106 Schneider R, Egan J, Houser V. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes [abstract]. Diabetes 1999; 42Suppl. 1: A106
38.
go back to reference Matthews DR, Bakst A, Weston WM, et al. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes [abstract]. Diabetologia 1999; 42Suppl. 1: A228 Matthews DR, Bakst A, Weston WM, et al. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes [abstract]. Diabetologia 1999; 42Suppl. 1: A228
39.
go back to reference Mathisen A, Egan J, Schneider R. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes [abstract]. Diabetes 1999; 42Suppl. 1: A106 Mathisen A, Egan J, Schneider R. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes [abstract]. Diabetes 1999; 42Suppl. 1: A106
40.
go back to reference Beebe K, Patel J. Rosiglitazone is effective and well-tolerated in patients ≥65 years with type 2 diabetes [abstract]. Diabetes 1999; 42Suppl. 1: A111 Beebe K, Patel J. Rosiglitazone is effective and well-tolerated in patients ≥65 years with type 2 diabetes [abstract]. Diabetes 1999; 42Suppl. 1: A111
41.
go back to reference Guay DR. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy 1998; 18: 1195–204PubMed Guay DR. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy 1998; 18: 1195–204PubMed
42.
go back to reference Ramirez J. Strategies to improve management of type 2 diabetes mellitus. BioMedicina 1999; 2: 27–39 Ramirez J. Strategies to improve management of type 2 diabetes mellitus. BioMedicina 1999; 2: 27–39
43.
go back to reference Zimmerman BR, Hagen MD. An evaluation of new agents in the treatment of type 2 diabetes. J Fam Pract 1998; 47 Suppl.: S37–43PubMed Zimmerman BR, Hagen MD. An evaluation of new agents in the treatment of type 2 diabetes. J Fam Pract 1998; 47 Suppl.: S37–43PubMed
44.
go back to reference Wolffenbuttel BHR, Graal MB. New treatments for patients with type 2 diabetes mellitus. Postgrad Med J 1996; 72: 657–62PubMedCrossRef Wolffenbuttel BHR, Graal MB. New treatments for patients with type 2 diabetes mellitus. Postgrad Med J 1996; 72: 657–62PubMedCrossRef
45.
go back to reference Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83: 1515–22PubMedCrossRef Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998; 83: 1515–22PubMedCrossRef
46.
go back to reference Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443–51PubMedCrossRef Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443–51PubMedCrossRef
47.
go back to reference Blodgett J. Alpha-glucosidase inhibitors. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book; 1998: 105–8 Blodgett J. Alpha-glucosidase inhibitors. In: DeFronzo RA, editor. Current therapy of diabetes mellitus. St Louis (MO): Mosby-Year Book; 1998: 105–8
49.
go back to reference Rosenstock J, Schwartz S, Clark C, et al. Efficacy and safety of HOE901 (insulin glargine) in subjects with type 2 DM: a 28-week randomized, NPH insuln-controlled trial [abstract]. Diabetes 1999; 42Suppl. 1: A100 Rosenstock J, Schwartz S, Clark C, et al. Efficacy and safety of HOE901 (insulin glargine) in subjects with type 2 DM: a 28-week randomized, NPH insuln-controlled trial [abstract]. Diabetes 1999; 42Suppl. 1: A100
50.
go back to reference Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998; 20: 86–496CrossRef Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998; 20: 86–496CrossRef
51.
go back to reference Coscelli C, Lostia S, Lunetta M, et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 1995; 28: 173–7PubMedCrossRef Coscelli C, Lostia S, Lunetta M, et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 1995; 28: 173–7PubMedCrossRef
52.
go back to reference Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998; 21: 1052–7PubMedCrossRef Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998; 21: 1052–7PubMedCrossRef
Metadata
Title
Management of Type 2 Diabetes Mellitus in the Elderly
Special Considerations
Author
Dr Julio Rosenstock
Publication date
01-01-2001
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 1/2001
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200118010-00003

Other articles of this Issue 1/2001

Drugs & Aging 1/2001 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.